Loading
Life sciences · Journal article
Clinical Oral Investigations · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Objectives This study evaluated the incidence of MRONJ and associated factors among breast cancer patients with bone metastases in Finland. Materials and methods This retrospective cohort study included all adult patients with breast cancer and bone metastases who were prescribed antiresorptive therapy between 2013 and 2015. Patients were identified from national health care registers and followed through 2020. The outcome variable was MRONJ (M87.1). Covariates included age, oral diseases, dental procedures, type of antiresorptive (AR) prescribed, comorbidities, and concomitant medications. Results A total of 652 patients met the inclusion criteria. The incidence of MRONJ ranged from 0% to 2.2% among bisphosphonate users, compared with 12.6% among denosumab users and 15.3% among patients receiving sequential bisphosphonate and denosumab therapy. Both denosumab monotherapy and sequential bisphosphonate-denosumab therapy were associated with substantially increased MRONJ risk compared with bisphosphonate therapy. Conclusions Denosumab use and infection-related invasive dental procedures showed the strongest associations with MRONJ in this study population. Clinical relevance MRONJ incidence differed by type of antiresorptive therapy, with higher occurrence among patients using denosumab or bisphoshonates followed by denosumab compared with bisphosphonates. MRONJ was more frequent among patients who underwent infection-related invasive dental procedures.